孟鲁司特联合布地奈德治疗咳嗽变异性哮喘的效果及对炎性介质的影响

Effect of montelukast combined with budesonide in the treatment of cough variant asthma and its influence on inflammatory mediators

目的探讨孟鲁司特联合布地奈德治疗咳嗽变异性哮喘的效果及对炎性介质的影响。方法选取150例咳嗽变异性哮喘患儿作为研究对象,按照用药方式将其分为对照组(75例,布地奈德)和观察组(75例,孟鲁司特联用布地奈德)。比较两组的治疗效果。结果治疗1、2个月后,观察组的FEV1%、PEF%、FEV1/FVC均优于对照组(P<0.05);治疗后,两组患儿的TNF-α、IL-4、IL-5水平均下降,且观察组明显低于对照组(P<0.05);治疗后,两组的IgE、IgG水平及咳嗽症状、LCQ评分均改善,且观察组明显优于对照组(P<0.05)。结论孟鲁司特联用布地奈德能有效改善咳嗽变异性哮喘患儿肺功能指标,减少炎性介质释放,改善免疫功能,提高生存质量,值得临床推广。

Objective To investigate the effect of montelukast combined with budesonide in the treatment of cough variant asthma and its influence on inflammatory mediators.Methods A total of 150 children with cough variant asthma were selected as the research objects and divided into control group(75 cases,budesonide)and observation group(75 cases,montelukast combined with budesonide)according to the way of medication.The therapeutic effect of the two groups was compared.Results After 1 and 2 months of treatment,FEV1%,PEF%and FEV1/FVC in the observation group were better than those in the control group(P<0.05);after treatment,the levels of TNF-α,IL-4 and IL-5 in the two groups decreased,and those in the observation group were significantly lower than the control group(P<0.05);after treatment,IgE and IgG levels,cough symptoms and LCQ scores in both groups improved,and those in the observation group were significantly better than the control group(P<0.05).Conclusion Montelukast combined with budesonide can effectively ameliorate the pulmonary function indexes,reduce the release of inflammatory mediators,and improve immune function and the quality of life of children with cough variable asthma,which is worthy of clinical promotion.